Seer, Inc. is a California-based pharmaceutical company in the United States that specializes in biotechnology. With an ESG risk rating score of 27.0, the company is considered to have a medium risk assessment. Seer, Inc. is known for commercializing transformative products for researchers to access unbiased biological information. Their flagship product, the Proteograph Product Suite, utilizes proprietary engineered nanoparticle technology to provide deep, rapid, and large-scale access across the proteome.